期刊档案 · Engineering-Biomedical Engineering

Translational Vision Science & Technology

ISSN 2164-2591 · Association for Research in Vision and Ophthalmology Inc. · UNITED STATES

Translational Vision Science & Technology 中科院 医学 2区(2025 年升级版),影响因子 2.72,完全开放获取,APC 约 1,850 美元,投稿社区反馈审稿约 25 周,2025 年发文 392 篇,SCIE、Scopus 收录。

影响因子2.72LetPub 汇总的最新公布值
中科院分区医学 2区2025 年升级版大类 · 2026 新锐版 医学 3区
审稿周期约 25 周投稿社区平均反馈
版面费1,850 USD完全开放获取
录用比例—暂无反馈
年发文量392 篇2025 年 · OpenAlex 统计

研究范围

研究范围与定位

Translational Vision Science & Technology 由 Association for Research in Vision and Ophthalmology Inc. 出版,属中科院医学大类(2025 升级版2区)。按 OpenAlex 近年发文统计,该刊主要发表 Retinal Diseases and Treatments、Glaucoma and retinal disorders、Ophthalmology and Visual Impairment Studies 等主题的论文,这 3 个主题约占 40.3%,主导子领域为 Radiology, Nuclear Medicine and Imaging。(根据 OpenAlex 主题统计与中科院分区数据生成)

The conceptualization of translational research has expanded since the inception of Translational Vision Science and Technology (TVST). The expanded scope of translational research necessitates that we likewise expand the scope of the journal. TVST will publish work that fits into phases T1 through T4 translational research. Some examples are as follows: T1: Development and validation of animal models, preclinical drug studies, development of clinically relevant technologies, and phase 1 and 2 clinical studies (“bench to bedside” research). T2: Phase 3 clinical trials (including comparative effectiveness trials), phase 4 clinical research, and development of clinical guidelines (“bedside to practice” research). T3: Research focused on implementation and dissemination of phase 3 and 4 clinical research results (dissemination and implementation research). T4: Research focused on outcomes and effectiveness in populations, including assessment of benefit to communities through public health policies and programs, as well as adoption of proven interventions’ best practices in communities (diffusion research), and cost-benefit analyses. This classification scheme is best conceived as a continuum, a natural progression of investigative activity, rather than as a series of clearly defined categories. As a result of the change in scope, the number and diversity of publications accepted by the journal is likely to increase compared with past years. ARVO's commitment to this expanded scope will enable TVST to better represent the diversity of research that is already represented in platform and poster presentations at the annual ARVO meeting. This scope change will enable ARVO to represent the interests of its members and to advance the development and assessment of treatments for blinding diseases worldwide. *For a more detailed description and discussion please see Marco Zarbin's editorial at TVST 2020;9(8):22. Short updates on new developments and controversies will be published by invitation. TVST encourages the use of color, multimedia, hyperlinks, program code and other digital enhancements. TVST will utilize and take advantage of every technological innovation afforded by digital data management to optimize TVST’s computer-based reading experience. Manuscripts from scientists and clinicians with diverse backgrounds ranging from basic chemistry to ophthalmic surgery, bringing together research that, until now, often has been published in journals other than tho

摘自期刊官网 Aims & Scope

研究方向(LetPub):Engineering-Biomedical Engineering

主编 Roy S. Chuck出版商官网

主要研究主题 OpenAlex 近年发文统计,占比为近似值

  1. Retinal Diseases and TreatmentsMedicine13.9%
  2. Glaucoma and retinal disordersMedicine13.7%
  3. Ophthalmology and Visual Impairment StudiesMedicine12.6%
  4. Retinal Imaging and AnalysisMedicine8%
  5. Corneal surgery and disordersMedicine7%
  6. Retinal and Macular SurgeryMedicine6.8%
  7. Retinal Development and DisordersBiochemistry, Genetics and Molecular Biology5.8%
  8. Ocular Surface and Contact LensMedicine4.9%

分区与收录

学科分区与数据库收录

中科院期刊分区表

期刊分区表( 2025年3月升级版)医学 2 区
类别学科分区
大类医学2 区
小类眼科学OPHTHALMOLOGY2 区

Top 期刊:否综述期刊:否

《新锐期刊分区表》( 2026年3月发布)医学 3 区
类别学科分区
大类医学3 区
小类眼科学OPHTHALMOLOGY2 区

Top 期刊:否综述期刊:未标注

期刊分区表( 2023年12月旧的升级版)医学 3 区
类别学科分区
大类医学3 区
小类眼科学OPHTHALMOLOGY3 区

Top 期刊:否综述期刊:否

数据库收录

SCIEScopusDOAJLetPub

国际期刊预警名单:各版本均未列入LetPub

不同版本、大类与小类分别展示,不将不同评价口径合并为一个分区值;投稿与考核前请确认所在机构采用的版本。

指标

影响力指标与发文规模

影响力指标

影响因子
2.72LetPub ·
CiteScore 2026-06
4.6LetPub ·
SJR 2026-06
0.94LetPub ·
SNIP 2026-06
1.05LetPub ·
h-index
12LetPub ·
h-index
72OpenAlex ·
i10-index
1,534OpenAlex ·
两年平均被引
3.08OpenAlex ·
自引率
7.4%LetPub ·
Gold OA 文章占比
99.61%LetPub ·

发文规模

年文章数
377LetPub ·
年发文量(出版商公布)
2,012出版商官网 ·

逐年发文量 OpenAlex 统计 · 累计 3,360 篇 · 当年数据不完整

年份发文量其中 OA被引
202627927978
2025392392880
20243653652,231
20233283282,943
20223633634,672
20214314317,322

不同来源的统计口径与观测时间不同,页面保留各来源原值;“出版商公布”为期刊官网自述数据。

审稿与录用

审稿周期与录用情况

平均审稿速度(社区反馈)
25 WeeksLetPub ·
投稿到发表(期刊自报)
约 25 周DOAJ ·
评审方式
同行评审(未说明方式)DOAJ

社区反馈来自投稿者样本,置信度 0.5,不代表期刊承诺;“出版商公布”的时间节点定义以官网为准。

费用与开放获取

版面费与开放获取政策

完全开放获取DOAJ

所有文章开放获取,通常向作者收取文章处理费(APC)。

来源文章处理费费用减免许可证观测时间
DOAJUSD 1,850有CC BY、CC BY-NC-ND
OpenAlexUSD 1,850——
出版商官网USD 300 / USD 1,950 / USD 350——

费用以期刊官网为准;不同来源的观测时间可能不同,页面保留各来源原值,不做平均。

投稿要求

文章类型与投稿政策(官网)

征稿中的专刊1 个,按截稿日期
  1. Call for papers截稿
出版商官网
官网政策摘录AI 使用、作者资格、许可与版权
AI 使用 ARVO Artificial Intelligence Policy

This policy covers the use of generative artificial intelligence (AI) technologies such as Large Language Models (e.g., ChatGPT, GPT-4, Dolly) and text-to-image generators (e.g., DALL-E 2, DeepAI) for manuscripts submitted to ARVO journals (IOVS, JOV, or TVST). Use of AI by Authors A generative AI technology cannot be listed as a co-author or author of any submitted manuscript. If the author of a …

原文 ↗出版商官网 ·
作者资格 Authorship

The decision on who to include as an author should be discussed and agreed upon prior to the initial submission. For guidelines regarding authorship, please see the ARVO Journals Uniform Policy Regarding Publication Ethics. If at any time during the peer review process there is a change to the authorship listing, then authors must complete a Change of Authorship form. When removing an author, only…

原文 ↗出版商官网 ·
许可与版权 Copyright

Prior Publication/Duplicate Submission All submissions must be original. Manuscripts are subjected to iThenticate plagiarism detection and Imagetwin image integrity analysis prior to review. Manuscripts will not be considered that have been previously published, in full, or in part, in any format, except as an abstract, academic thesis, or in draft form on a non-peer reviewed preprint server. Auth…

原文 ↗出版商官网 ·

摘录来自期刊官网页面,仅保留原文片段;“模型摘要”由 Workers AI 生成并经原文校验,以官网为准。

基本信息

出版信息与官方入口

出版商
Association for Research in Vision and Ophthalmology Inc.
出版国家或地区
UNITED STATES
出版语言
English
ISSN
2164-2591
学会 / 主办单位
Association for Research in Vision and Ophthalmology
官网最新一期
Volume 15, Issue 9(2026 年 9 月)
官方链接

常见问题

关于 Translational Vision Science & Technology 的常见问题

Translational Vision Science & Technology 是中科院几区期刊?

2025 年升级版分区表中,Translational Vision Science & Technology 为医学 2区,小类 眼科学 2 区。2026 年新锐版分区表中为医学 3区。不同版本与大小类分区不能混用。

Translational Vision Science & Technology 的影响因子是多少?

LetPub 汇总的最新公布影响因子为 2.72,CiteScore 为 4.6,h-index 为 72。

Translational Vision Science & Technology 的审稿周期多长?

投稿社区反馈的平均审稿速度为约 25 周。文章统计只含被录用的稿件,出版商数据口径以官网为准,社区反馈来自投稿者样本,均不代表期刊承诺。

Translational Vision Science & Technology 被哪些数据库收录?

据 LetPub 与 DOAJ 记录,Translational Vision Science & Technology 被 SCIE、Scopus、DOAJ 收录。

Translational Vision Science & Technology 是开放获取期刊吗?版面费多少?

Translational Vision Science & Technology 为完全开放获取。APC 约 1,850 美元。

来源与更新

本页事实来自 LetPub、OpenAlex、DOAJ、出版商官网;每个数字旁标注来源与观测日期,冲突数据保留各来源原值。LetPub 原始详情页:查看 ↗(2026-08-26 归档)。最近更新:。